"We are excited to have Dr. Lau and Dr. Sidransky join Morria's board," said Mark Cohen, chairman of the board. "Their extensive pharmaceutical and corporate experience will provide valuable guidance in both our clinical development plan with our lead anti-inflammatory compounds and the development of the company from a corporate perspective."
ABOUT MORRIA BIOPHARMACEUTICALS Plc
Morria Biopharmaceuticals Plc is a biopharmaceutical company focused on the development of novel anti-inflammatory pharmaceuticals known as multi- functional anti-inflammatory drugs (MFAIDs). The company's objective is to become a pivotal player in the anti-inflammatory drug market through the introduction of novel drugs for the treatment of a variety of acute and chronic inflammatory conditions including skin, pulmonary and gastro- intestinal inflammatory diseases. For more information please visit http://www.morria.com.
This is not an invitation nor is it an offer to purchase or subscribe for shares. This release is only intended for persons falling within the exception set out in regulation 47 of the Financial Promotion order - persons in the business of disseminating information.
SOURCE: Morria Biopharmaceuticals Plc
UK CONTACT: Yuval Cohen, President
53 Davies Street, London, W1K 5JH, United Kingdom
Tel: +44 (0) 207 152 6341 or email@example.com
US CONTACT: Greg Tiberend
Richard Lewis Communications, Inc.
35 West 35 St., Suite 505, New York, NY 10001
Tel: +1 212-827-0020 or firstname.lastname@example.org
|SOURCE Morria Biopharmaceuticals Plc|
Copyright©2007 PR Newswire.
All rights reserved